MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don’t get them

MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don’t get them Prostate cancer is the most commonly diagnosed cancer in the United States, with over 333,000 new cases recorded annually. Despite its prevalence, it is also the least deadly form of cancer, with only about 4% of cases resulting in death. The 5-year survival rate stands at approximately 99%, highlighting the effectiveness of current diagnostic and treatment strategies. However, this success comes at a cost: many men receive unnecessary treatments for low-grade tumors that pose minimal threat to their health. The current diagnostic process typically begins with a blood test measuring prostate-specific antigen (PSA) levels. If the results indicate elevated PSA, a systematic biopsy is performed to identify cancerous tissue. While this method is effective at detecting cancer early, it leads to a significant overdiagnosis issue. Up to 70% of newly diagnosed cases are classified as low grade, meaning they rarely progress to a life-threatening stage. Yet, a substantial portion, up to 50% or more, of these men undergo treatment, according to data from the American Urological Association Quality Registry. Some healthcare providers even treat nearly all patients with low-grade cancer, raising concerns about the necessity of such interventions. Experts in the field argue that these low-grade lesions should not be labeled as cancer at all. Scott Eggener, a professor of urology at the University of California, Los Angeles, suggests that the widespread classification of such conditions as cancer contributes to the high rates of overdiagnosis. He and other specialists believe that the term “cancer” is being misapplied in these instances, leading to unnecessary medical procedures and psychological distress. This situation is unique to the United States. In other parts of the world, including Europe, Canada, Australia, and the United Kingdom, the approach to diagnosing prostate cancer is markedly different. Over the past 15 years, magnetic resonance imaging (MRI) scans have become the preferred initial step following an elevated PSA result, helping to determine whether a biopsy is necessary. Between 30% and 50% of patients can avoid a biopsy through an MRI, thereby reducing the likelihood of discovering clinically insignificant cancer and minimizing the risks associated with biopsies. While the use of pre-biopsy MRI has been incorporated into U.S. guidelines since 2020, its adoption remains limited. According to the latest available data, MRIs were used in less than a third of cases in the U.S. in 2022. The remaining cases proceeded directly to systematic biopsies, despite evidence from studies such as the 2018 PRECISION trial showing that MRIs lead to better outcomes by identifying more cancer while reducing the incidence of clinically insignificant diagnoses. Several factors contribute to the slow adoption of MRI in the U.S. These include the gradual integration of new medical technologies, the lack of familiarity among some urologists with interpreting MRI images, and financial incentives tied to performing biopsies. As a result, many men continue to face the risks associated with unnecessary biopsies, which can lead to complications and emotional distress. Mark Emberton, a professor of Interventional Oncology at University College London, has criticized the U.S. approach as one of the worst global health scandals. He notes that the wealthiest nation in the world is denying its men access to a diagnostic tool that has been widely adopted elsewhere and supported by robust scientific evidence. His comments underscore the disparity in medical practices and highlight the urgent need for change in the U.S. healthcare system.